Sickle cell S-D Punjab disease

Sickle cell S-D Punjab disease (also known as hemoglobin SD disease or HbSD-Punjab disease) is a rare sickle cell syndrome caused by the co-inheritance of one hemoglobin S (HbS) allele and one hemoglobin D-Punjab (HbD-Punjab) allele in the beta-globin gene (HBB). Hemoglobin D-Punjab (also called HbD-Los Angeles) results from a glutamic acid to glutamine substitution at position 121 of the beta-globin chain. Although HbD-Punjab trait alone is clinically benign, when inherited together with HbS, the resulting compound heterozygous state produces a clinically significant sickling disorder that can be as severe as homozygous sickle cell disease (HbSS). The disease primarily affects the hematologic system, with chronic hemolytic anemia being a hallmark feature. Red blood cells containing the abnormal hemoglobins polymerize under low-oxygen conditions, leading to the characteristic sickle-shaped cells that can obstruct small blood vessels. This vaso-occlusion causes recurrent painful crises, acute chest syndrome, splenic sequestration, and progressive organ damage affecting the spleen, kidneys, bones, lungs, and brain. Patients may experience fatigue, jaundice, and increased susceptibility to infections, particularly due to functional asplenia that often develops in childhood. Management of sickle cell S-D Punjab disease follows the general principles used for sickle cell disease. Treatment includes pain management during vaso-occlusive crises, hydroxyurea therapy to increase fetal hemoglobin levels and reduce crisis frequency, prophylactic antibiotics and vaccinations to prevent infections, folic acid supplementation, and blood transfusions when clinically indicated. Hematopoietic stem cell transplantation may be considered in severe cases and represents the only currently established curative option. Early diagnosis through newborn screening programs and comprehensive multidisciplinary care are important for improving outcomes.

Common questions about Sickle cell S-D Punjab disease